Date: 2015-03-05
Type of information: Nomination
Compound:
Company: Thrombogenics (Belgium)
Therapeutic area: Ophtalmological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 5, 2015, ThromboGenics, an integrated biopharmaceutical company focused on developing and commercializing innovative medicines for the treatment of vitreo-retinal diseases, announced that Joseph Markoff, Ph.D., M.D. has joined the Company as Scientific Advisor. Dr. Markoff will report to Paul G. Howes, Executive Chairman of ThromboGenics Inc., and work with the Medical Affairs team in the U.S. and the global Clinical Development team. Dr. Markoff has over 35 years of experience as an ophthalmic surgeon at the Wills Eye Hospital in Philadelphia, PA. He has directed the hospital\'s Visual Physiology service for the past 32 years and also holds the rank of Attending Surgeon and Clinical Professor of Ophthalmology at Thomas Jefferson University Medical School. Dr. Markoff founded Philadelphia Eye Associates, a leading private eye care practice in the Philadelphia area. From February 2010 till recently, he assumed the role as Global Director for Scientific Affairs in Ophthalmology at Merck & Co., Inc. Hehas conducted over 50 clinical trials during his career sponsored by companies such as Alcon, Allergan, Pfizer, Pharmacia and Merck & Co.
Financial terms:
Latest news:
